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Abstract
Background: Cerebrovascular dysfunction has been considered to cause impairment of cerebral amyloid-b peptide
(Ab) clearance across the blood-brain barrier (BBB). Further, low levels of vitamin D are associated with increased
risk of Alzheimer’s disease, as well as vascular dysfunction. The purpose of the present study was to investigate the
effect of 1a,25-dihydroxyvitamin D3 (1,25(OH)2D3), an active form of vitamin D, on cerebral Ab clearance from
mouse brain.
Methods: The elimination of [
125I]hAb(1-40) from mouse brain was examined by using the Brain Efflux Index
method to determine the remaining amount of [
125I]hAb(1-40) radioactivity after injection into the cerebral cortex.
[
125I]hAb(1-40) internalization was analyzed using conditionally immortalized mouse brain capillary endothelial cells
(TM-BBB4).
Results: Twenty-four hours after intraperitoneal injection of 1,25(OH)2D3 (1 μg/mouse), [
125I]hAb(1-40) elimination
from mouse brain was increased 1.3-fold, and the level of endogenous Ab(1-40) in mouse brain was reduced.
These effects were observed at 24 h after i.p. injection of 1,25(OH)2D3, while no significant effect was observed at
48 or 72 h. Vitamin D receptor (VDR) mRNA was detected in mouse brain capillaries, suggesting that 1,25(OH)2D3
has a VDR-mediated genomic action. Furthermore, forskolin, which activates mitogen-activated protein kinase
kinase (MEK), enhanced [
125I]hAb(1-40) elimination from mouse brain. Forskolin also enhanced [
125I]hAb(1-40)
internalization in TM-BBB4 cells, and this enhancement was inhibited by a MEK inhibitor, suggesting involvement of
non-genomic action.
Conclusions: The active form of vitamin D, 1,25(OH)2D3, appears to enhance brain-to-blood Ab(1-40) efflux
transport at the BBB through both genomic and non-genomic actions. Compounds activating these pathways may
be candidate agents for modulating Ab(1-40) elimination at the BBB.
Background
An abnormally elevated level of amyloid-b peptide (Ab)
in the brain is one of the prominent features of Alzhei-
mer’s disease (AD) [1]. Ab is normally produced by neu-
rons and cleared through degradation by proteinases
within the brain [2-4], as well as through elimination
from the brain to the circulating blood via an efflux
transport system at the blood-brain barrier (BBB) [5,6].
It has been proposed that impairment of cerebral Ab
clearance leads to abnormally elevated brain Ab levels
in late-onset AD which accounts for more than 90% of
all cases of AD. On the other hand, somatostatin was
reported to promote the degradation of Ab in the brain
[7]. Anti-Ab antibodies such as m266 in circulating
blood were also proposed to enhance Ab efflux trans-
port from brain to blood [8], though we subsequently
found that anti-Ab antibodies did not promote Ab elim-
ination from brain to the blood across the BBB [9].
Identification of factors that promote cerebral Ab clear-
ance would be helpful in developing new therapeutic
approaches and agents for treatment and prevention of
AD.
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of serum 25-hydroxyvitamin D3 (25(OH)D3), the major
circulating form of vitamin D, is associated with cogni-
tive impairment in elderly persons [10-12] and is a risk
factor for AD [13,14]. Furthermore, it was reported that
single nucleotide polymorphisms in the vitamin D
receptor (VDR) gene increase the risk of impairment of
cognitive function and developing AD [15,16], suggest-
ing a relation between serum vitamin D levels and risk
of AD. It was also reported that low levels of serum 25
(OH)D3 are associated with increased risk for cardiovas-
cular diseases, hypertension and diabetes mellitus
[17-20], which are associated with vascular dysfunction.
Since clinical studies have provided evidence that vascu-
lar dysfunction plays an important role in early progres-
sion of AD [21-23], we hypothesized that serum vitamin
D affects the function of brain capillaries, including the
brain-to-blood efflux transport of Ab.
T h ep u r p o s eo ft h ep r e s e n ts t u d yw a st oi n v e s t i g a t e
the effect of 1a,25-dihydroxyvitamin D3 (1,25(OH)2D3),
the physiologically active form of vitamin D, on the
elimination of human Ab(1-40) (hAb(1-40)) from mouse
brain across the BBB using the Brain Efflux Index (BEI)
method. We also examined the internalization of [
125I]
hAb(1-40) in conditionally immortalized mouse brain
capillary endothelial cells (TM-BBB4), as an in vitro
BBB model [24].
Methods
Animals
Male C57BL/6 mice (8-10 weeks old) were purchased
from Japan SLC (Hamamatsu, Japan). All experiments
were approved by the Animal Care Committee of the
Graduate School of Pharmaceutical Sciences, Tohoku
University.
Reagents
Monoiodinated, non-oxidized and lyophilized [
125I]hAb
(1-40) labeled from hAb(1-40) (Biosource, CA, USA)
was from PerkinElmer Life Sciences (Boston, MA, USA)
(2,200 Ci/mmol). [
3H]Dextran (100 mCi/mg) was
obtained from American Radiolabeled Chemicals, Inc.
(St. Louis, MO, USA). 1,25(OH)2D3 was obtained from
Biomol Research Laboratories (Plymouth Meeting, PA,
USA). Forskolin and xylazine hydrochloride were pur-
chased from Sigma (St Louis, MO, USA). U0126 was
obtained from Calbiochem (Merck, Darmstadt, Ger-
many). Ketaral 50 (ketamine hydrochloride) was pur-
chased from Sankyo Co. (Tokyo, Japan). All other
chemicals were analytical grade commercial products.
In vivo BEI study
The mice were injected i.p. with 100 μL of 1,25(OH)2D3
at a dose of 0.2, 1 or 5 μg dissolved in H2O containing
5% ethanol, or forskolin at a dose of 2.3 or 23 μgd i s -
solved in 100 μLo fH 2O containing 25% dimethyl sulf-
oxide. Control mice were injected i.p. with 100 μLo f
each vehicle solution. After an indicated time (24, 48, or
72 h), the in vivo brain elimination experiments were
performed using the intracerebral microinjection techni-
que [25]. Briefly, mice were anesthetized with an intra-
muscular injection of xylazine (1.22 mg/kg) and
ketamine (125 mg/kg), and placed in a stereotaxic frame
( S R S - 6 ;N a r i s h i g e ,T o k y o ,J a p a n )t h a td e t e r m i n e st h e
coordinates of the mouse brain coinciding with the sec-
ondary somatosensory cortex 2 (S2) region. A small
hole was made 3.8 mm lateral to the bregma, and a fine
injection needle fitted to a 5.0 μlm i c r o s y r i n g e( H a m i l -
ton, Reno, NE, USA) was advanced to a depth of 2.5
mm. The solution of [
125I]hAb(1-40) was freshly pre-
pared from lyophilized [
125I]hAb(1-40) immediately
before each experiment. Lyophilized [
125I]hAb(1-40) was
solubilized in H2O and then added to an equal volume
of 2-fold concentration of extracellular fluid (ECF) buf-
fer (244 mM NaCl, 50 mM NaHCO3,6m MK C l ,2 . 8
mM CaCl2,2 . 4m MM g S O 4,0 . 8m MK 2HPO4,2 0m M
D-glucose, and 20 mM HEPES, pH 7.4). Gel filtration
analysis confirmed that a single peak of monomer [
125I]
hAb(1-40) was detected, and 98.3% of the radioactivity
was recovered, suggesting that release of free [
125I] was
negligible [26]. The applied solution (0.3 μl) containing
[
125I]hAb(1-40) and [
3H ] d e x t r a ni na nE C Fb u f f e rw a s
administered into the S2 region over a period of 30 sec.
After microinjection, the microsyringe was left in place
for 4 min to minimize any backflow. At 5, 30 or 60 min
after microinjection, ipsilateral (left) and contralateral
(right) cerebrum and cerebellum were excised and dis-
solved in 2.0 ml 2 M NaOH at 60°C for 1 h. The
125I
and
3H radioactivities of the samples were measured in
a g-counter (ART300, Aloka, Tokyo, Japan) for 3 min
and a liquid scintillation counter (TRI-CARB2050CA,
Packard Instruments, Meriden, CT, USA) for 5 min,
respectively. The BEI was defined by Equation (1), and
the percentage of substrate remaining in the ipsilateral
cerebrum (100-BEI) was determined using Equation (2):
BEI (% ) =
test substrate undergoing efﬂux at the BBB
test substrate injected into the brain
x1 0 0
100 - BEI (% ) =
amount of test substrate in the brain
amount of reference in the brain
concentration of test substrate injected
concentration of reference injected
x1 0 0
The apparent elimination rate constant (kel)w a s
determined from the slope given by fitting a semiloga-
rithmic plot of (100-BEI) versus time, using the non-
linear least-squares regression analysis program MULTI
[27].
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ELISA
Endogenous soluble Ab(1-40) in mouse brain extracts
was quantified according to the previously-reported
method [28]. Twenty-four h after 1,25(OH)2D3 (1 μg/
mouse) or vehicle injection i.p., mice were sacrificed and
the brains were rapidly isolated. The cerebellum and
olfactory bulbs were discarded, and the remaining brains
were snap-frozen in liquid nitrogen. To extract soluble
endogenous full-length mouse Ab(1-40), the frozen
brains were homogenized in 10 volumes of ice-cold Tris
buffer (50 mM Tris-HCl, 250 mM sucrose and protease
inhibitor cocktail (Sigma, St. Louis, MO, USA)). Samples
were mixed in diethylamine (DEA) to yield 0.4% con-
centration and centrifuged at 100,000 × g for 45 min at
4°C. The resultant supernatant was neutralized in 1/10
volume of 0.5 M Tris-HCl (pH 6.8) and used for analy-
sis. Endogenous full-length mouse Ab(1-40) levels were
determined using an ELISA (IBL, Gunma, Japan)
according to the manufacturer’s protocol.
TM-BBB4 cell culture
The TM-BBB4 cell line, established from transgenic
mice harboring the temperature-sensitive SV40 large T-
antigen gene [24], was used in this study. TM-BBB4
cells were cultured at 33°C in Dulbecco’sm o d i f i e d
Eagle’s medium (DMEM; Nissui Pharmaceutical Co.,
Tokyo, Japan), supplemented with 20 mM NaHCO3,2
mM L-glutamine, 15 ng/ml endothelial cell growth fac-
tor, 100 U/ml benzyl penicillin, 100 mg/ml streptomycin
sulfate, and 10% fetal bovine serum (Moregate, Bulimba,
Australia) in an atmosphere of 95% air and 5% CO2.
RT-PCR analysis
Isolated mouse brain capillaries were prepared as
described previously [29]. Total RNA was prepared from
isolated mouse brain capillaries, TM-BBB4 cells and
mouse brain using TRIzol reagent (Life Technologies,
Grand Island, NY, USA) and RNeasy plus kit (Qiagen,
Tokyo, Japan) according to the manufacturer’sp r o t o -
cols. Single-stranded cDNA was prepared from 1 μgo f
total RNA by means of reverse transcription (DNA Liga-
tion Kit, Takara, Osaka, Japan) using oligo dT primer.
The PCR was performed with GeneAmp (PCR system
9700, Perkin-Elmer, Norwalk, CT, USA) using specific
primers through 1 cycle of 94°C for 2 min, and 35 cycles
of 94 °C for 30 s, 55°C for 30 s and 72°C for 1 min and
finally 72°C for a further 5 min. The sequences of the
primers were as follows: sense primer 5’-CGA TGC
CCA CCA CAA GAC CTAC-3’ and antisense primer
5’-CAG CAT GGA GAG CGG AGA CAG-3’ for vita-
min D receptor (GenBank Accession Number,
NM_009504), sense primer 5’-TTT GAG ACC TTC
AAC ACCC C-3’ and antisense primer 5’-ATA GCT
CTT CTC CAG GGA GG-3’ for b-actin (GenBank
Accession Number, NM_031144). The RT-PCR of each
sample RNA in the absence of reverse transcriptase was
used as a negative control. The RT-PCR products were
separated by electrophoresis on an agarose gel in the
presence of ethidium bromide (0.6 μg/mL) and visua-
lized using an imager (EPIPRO 7000; Aisin, Aichi,
Japan).
In vitro internalization study in TM-BBB4 cells
TM-BBB4 cells were seeded on 24-well plates (Becton
Dickinson, Bedford, MA, USA) at a density of 1.0 × 10
5
cells/2 cm
2/well and cultured for 24 h. The cells were
treated with the indicated concentrations of forskolin
and U0126 or vehicle for 24 h, and then internalization
of [
125I]hAb(1-40) into TM-BBB4 cells was examined as
previously described [26]. Briefly, the extent of TM-
BBB4 cell-[
125I]hAb(1-40) (0.15 μCi/200 μli nE C Fb u f -
fer) binding was measured for 3 min at 37°C. After the
indicated times, binding was terminated by removing
the solution, and the cells were washed three times with
1 ml ice-cold ECF buffer. The cells were then incubated
with 1 ml ice-cold acetate-barbital buffer (28 mM
CH3COONa, 120 mM NaCl, 20 mM barbital sodium
(pH 3.0) and 360 mOsm/kg) for 20 min at 4°C to
remove [
125I]hAb(1-40) bound to the cell surface. After
incubation, the buffer was then recovered (acid-soluble
fraction) and the cells were subsequently washed three
times with ice-cold acetate-barbital buffer.
Acid-resistant binding represents the amount of inter-
nalized [
125I]hAb(1-40) in the TM-BBB4 cells. The cells
were solubilized with 200 μlo f5MN a O Ho v e r n i g h t
and neutralized with 200 μl of 5 M HCl. The
125Ir a d i o -
activity was measured using a g-counter (ART310,
Aloka, Tokyo, Japan). The protein content of the cul-
tured cells was measured using a DC protein assay kit
(Bio-Rad, Hercules, CA, USA) with bovine serum albu-
min as a standard.
Data analysis
Unless otherwise indicated, all data represent the mean
± SEM. Unpaired two-tailed Student’s t-tests were used
to determine the significance of differences between the
means of two groups. One-way analysis of variance fol-
lowed by Dunnett’s test was used to assess the statistical
significance of differences among the means of more
than two groups.
Results
Effect of 1,25(OH)2D3 on the brain-to-blood efflux
transport rate of [
125I]hAb(1-40) at the BBB
To examine the effect of 1,25(OH)2D3 treatment on
brain-to-blood [
125I]hAb(1-40) efflux transport across
the BBB, the time profile of the percentage of [
125I]hAb
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ined at 24 h after i.p. administration of a single dose of
1,25(OH)2D3 (1 μg/mouse) (Figure 1). [
125I]hAb(1-40)
was eliminated from the brain in a time-dependent
manner after the administration of either 1,25(OH)2D3
or vehicle (Figure 1A). The percentage of [
125I]hAb(1-
40) remaining in 1,25(OH)2D3-treated mouse brain was
significantly lower than that in the vehicle-treatment
group at 60 min. The apparent elimination rate constant
across the BBB of [
125]hAb(1-40) determined from the
slope of the (100-BEI (%)) time profile was 2.38 × 10
-2 ±
0.09 × 10
-2 min
-1 (mean ± SD) in the 1,25(OH)2D3-trea-
ted group, which was significantly greater (1.29-fold)
than that of the vehicle-treated group (1.85 × 10
-2 ±
0.07 × 10
-2 min
-1, mean ± SD) (Figure 1B). The initial
percentage of [
125I]hAb(1-40) remaining in the mouse
brain treated with 1,25(OH)2D3 was 118% (Figure 1A),
which is not significantly different from that of the vehi-
cle-treated group (114%), indicating that the distribution
volume of [
125I]hAb(1-40) in the brain was not affected
by 1,25(OH)2D3 treatment. This suggests that 1,25(OH)
2D3-treatment did not affect hAb(1-40) binding to brain
parenchymal cells in mouse brain.
Dose and time dependence of 1,25(OH)2D3 action on
[
125I]hAb(1-40) elimination from mouse brain
Figure 2A shows the dose-dependence of 1,25(OH)2D3’s
effect on the percentage of [
125I]hAb(1-40) remaining in
the ipsilateral cerebrum at 60 min after microinjection;
this time point was chosen because the percentage of
[
125I]hAb(1-40) remaining decreased time-dependently up
to 60 min (Figure 1A, open circles). Twenty-four h after
single i.p. administration of 1,25(OH)2D3 (0.2, 1 and 5 μg/
Figure 1 Effect of 1,25(OH)2D3 on the elimination rate of [
125I]
hAb(1-40) from mouse brain. Mice received i.p. injection of 1,25
(OH)2D3 (1 μg dissolved in 100 μLo fH 2O containing 5% ethanol,
solid circles) or vehicle (100 μLo fH 2O containing 5% ethanol, open
circles). After 24 h, a mixture of [
125I]hAb(1-40) (0.012 μCi) and [
3H]
dextran (0.12 μCi) dissolved in 0.30 μL of ECF buffer was injected
into the S2 region of the brain. The solid line was obtained with the
non-linear least-squares regression analysis program, MULTI. Each
point represents the mean ± SEM (n = 3 - 5). (B) The elimination
rate constant of [
125I]hAb(1-40) from mouse brain after treatment
with 1,25(OH)2D3 (D3) or vehicle (V). Each bar represents the mean
± SD (n = 3 - 5). **p < 0.01, significantly different from vehicle-
treated group.
Figure 2 Effect of 1,25(OH)2D3 on amount of [
125I]hAb(1-40)
remaining in the ipsilateral cerebrum. (A) Dose-dependence of
the effect of 1,25(OH)2D3 on [
125I]hAb(1-40) elimination from mouse
brain. Mice received i.p. injection of 1,25(OH)2D3 (0.2, 1 or 5 μg
dissolved in 100 μLo fH 2O containing 5% ethanol) or vehicle (V,
100 μLo fH 2O containing 5% ethanol). After 24 h, a mixture of [
125I]
hAb(1-40) (0.012 μCi) and [
3H]dextran (0.12 μCi) dissolved in 0.30 μL
of ECF buffer was injected into the S2 region of the brain. Data,
obtained at 60 min after intracerebral microinjection, are presented
as the mean ± SEM (n = 5). (B) Time-course of the effect of i.p.
administration of 1,25(OH)2D3 on [
125I]hAb(1-40) elimination from
mouse brain. Mice received i.p. injection of 1,25(OH)2D3 (D3, 1 μg
dissolved in 100 μLo fH 2O containing 5% ethanol) or vehicle (V,
100 μLo fH 2O containing 5% ethanol). After 24, 48 and 72 h, a
mixture of [
125I]hAb(1-40) (0.012 μCi) and [
3H]dextran (0.12 μCi)
dissolved in 0.30 μL of ECF buffer was injected into the S2 region of
the brain. Data, obtained at 60 min after intracerebral
microinjection, are presented as the mean ± SEM (n = 4 - 5). *p <
0.05, **p < 0.01, significantly different from vehicle-treated group.
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125]hAb(1-40) remaining was
decreased by 12.9%, 25.4% and 19.5%, respectively, com-
pared with the vehicle-treated control (Figure 2A).
The effect of time after 1,25(OH)2D3 administration
was examined at the amount of 1 μg/mouse, which
exhibited the greatest effect in Figure 2A. As shown in
Figure 2B, a significant reduction of the percentage of
[
125]hAb(1-40) remaining was observed at 24 h after i.p.
administration of a single dose of 1,25(OH)2D3, com-
pared with the vehicle-treated control, while no signifi-
cant reduction was detected at 48 or 72 h after the i.p.
administration. No significant decrease was observed in
body weight or residual amount of [
3H]dextran, which is
an impermeable marker, in mouse brain up to 72 h
after the administration (data not shown), suggesting
t h a tas i n g l ed o s eo f1 , 2 5 ( O H ) 2D3 did not cause signifi-
cant toxicity or disruption of BBB integrity.
Effect of 1,25(OH)2D3 on the level of endogenous Ab(1-40)
in mouse brain
The effect of 1,25(OH)2D3 on soluble endogenous Ab(1-
40) level in mouse brain was examined by ELISA. Endo-
genous Ab(1-40) extracted with 0.4% DEA was signifi-
cantly decreased at 24 h after i.p. administration of a
single dose of 1,25(OH)2D3 compared with the vehicle-
treated group; the values were 723 ± 34 and 821 ± 30
fmol/g brain, respectively (p < 0.05, Figure 3).
mRNA expression of VDR in mouse brain, brain capillaries
and TM-BBB4 cells
1,25(OH)2D3 exerts its biological effects by transcrip-
tional activation of target genes via binding to the VDR.
RT-PCR analysis was performed to determine VDR
expression in mouse brain, mouse isolated brain capil-
laries and TM-BBB4 cells [24]. A band of the size pre-
dicted for VDR was obtained in each case (Figure 4),
suggesting that VDR is expressed in mouse brain capil-
lary endothelial cells.
Effect of forskolin on [
125I]hAb(1-40) elimination from
mouse brain
1,25(OH)2D3 also exerts non-genomic biological effects
via a complex signaling process, which has been
reported to involve increased levels of cyclic AMP
(cAMP) [30] and activation of the mitogen-activated
protein kinase kinase (MEK) pathway [31,32]. Since for-
skolin increases the level of cAMP following activation
of adenylyl cyclase in vitro, the effect of forskolin on the
remaining percentage of [
125I]hAb(1-40) in the ipsilat-
eral cerebrum was examined (Figure 5). Twenty-four h
after i.p. administration of single-dose forskolin (2.3 or
23 μg/mouse), the percentage of [
125I]hAb(1-40) remain-
ing in mouse brain was decreased by 16.4% in either
case compared with the vehicle-treated group at 60 min
after intracerebral [
125I]hAb(1-40) microinjection.
Effect of MEK inhibitor on the forskolin-induced
enhancement of [
125I]hAb(1-40) internalization by TM-
BBB4 cells
To determine whether MEK is involved in the forskolin-
induced enhancement of [
125I]hAb(1-40) elimination
from the brain, the effect of U0126, an inhibitor of MEK
activation, on [
125I]hAb(1-40) internalization into TM-
Figure 3 Effect of 1,25(OH)2D3 on the level of endogenous Ab
(1-40) in mouse brain. Mice received i.p. injection of 1,25(OH)2D3
(D3, 1 μg dissolved in 100 μLo fH 2O containing 5% ethanol) or
vehicle (V, 100 μLo fH 2O containing 5% ethanol). After 24 h, brain
levels of DEA-extracted mouse Ab(1-40) were measured by ELISA.
Each bar represents the mean ± SEM (n = 8). *p < 0.05, significantly
different from vehicle-treated group.
Figure 4 Expression of mRNAs for VDR and b-actin in mouse
brain, isolated brain capillaries and TM-BBB4 cells. RT-PCR
analysis was performed with specific primer sets as described in
Materials and Methods. Reactions were performed using total RNA
with (+) or without (-) reverse transcriptase (RT).
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125I]hAb
(1-40) bound to the cell surface was washed off with
acetate-barbital buffer (pH 3.0) after the uptake, and the
acid-resistant binding represents the amount of interna-
lized [
125I]hAb(1-40) in TM-BBB4 cells. Pre-treatment
with forskolin (10 μM) significantly increased the acid-
resistant binding of [
125I]hAb(1-40) by TM-BBB4 cells
(Figure 6A), indicating that [
125I]hAb(1-40) internaliza-
tion into TM-BBB4 cells was enhanced by forskolin
treatment (Figure 6A). As shown in Figure 6B, U0126
(25 μM) suppressed the forskolin-induced enhancement
of [
125I]hAb(1-40) acid-resistant binding. Pre-treatment
with U0126 alone significantly reduced the acid-resistant
binding of [
125I]hAb(1-40) by 11.2% compared with the
control. This reduction could be due to inhibition of
basal MEK activation and perhaps in part due to a toxic
effect of U0126, since the protein content of the cells
after the uptake was reduced by 19.8% by U0126 treat-
ment (89.8 ± 6.0 μg protein/well and 72.0 ± 7.0 μg pro-
tein/well, respectively, mean ± SEM, n = 4). The acid-
resistant binding of [
125I]hAb(1-40) was not significantly
different between the group pre-treated with U0126
alone and that treated with forskolin and U0126. The
protein content of the cells was not also affected
significantly (72.0 ± 7.0 μg protein/well for U0126 only
and 66.4 ± 3.9 μg protein/well for forskolin and U0126,
mean ± SEM, n = 4). This result suggests that MEK
activation is involved in the enhancement of Ab(1-40)
internalization by forskolin in TM-BBB4 cells.
Figure 5 Effect of forskolin on amount of [
125I]hAb(1-40)
remaining in the ipsilateral cerebrum. Mice received i.p. injection
of forskolin (2.3 and 23 μg dissolved in 100 μLo fH 2O containing
25% DMSO) or vehicle (V, 100 μLo fH 2O containing 25% DMSO).
After 24 h, a mixture of [
125I]hAb(1-40) (0.012 μCi) and [
3H]dextran
(0.12 μCi) dissolved in 0.30 μL of ECF buffer was injected into the S2
region of the brain. Data, obtained at 60 min after intracerebral
microinjection, are presented as the mean ± SEM (n = 4 - 5). *p <
0.05, significantly different from vehicle-treated group.
Figure 6 Involvement of ERK pathway in the uptake of [
125I]
hAb(1-40) by TM-BBB4 cells. (A) Effect of forskolin on [
125I]hAb(1-
40) internalization in TM-BBB4 cells. TM-BBB4 cells were treated with
1o r1 0μM forskolin for 24 h in culture medium containing 0.1%
DMSO. The acid-resistant binding of [
125I]hAb(1-40) (0.4 nM) was
measured at 3 min in TM-BBB4 cells. Each bar represents the mean
± SEM (n = 4). (B) Effect of MEK inhibitor, U0126, on [
125I]hAb(1-40)
internalization in TM-BBB4 cells. TM-BBB4 cells were treated with or
without forskolin (10 μM) and U0126 (25 μM) in culture medium
containing 0.1% DMSO for 24 h. The acid-resistant binding of [
125I]
hAb(1-40) (0.4 nM) was measured at 3 min in TM-BBB4 cells. Each
bar represents the mean ± SEM (n = 4). *p < 0.05, *** p < 0.001,
significant different from control or forskolin-treated group.
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Our results indicate that 1,25(OH)2D3 enhances cerebral
clearance of Ab(1-40) from mouse brain across the BBB.
Specifically, we have obtained in vivo evidence that 1,25
(OH)2D3 treatment significantly increased [
125I]hAb(1-
40) elimination from mouse brain across the BBB (Fig-
urs 1, 2), and resulted in a significant reduction in the
level of endogenous soluble Ab(1-40) in mouse brain
(Figure 3). The enhancement of [
125I]hAb(1-40) elimina-
tion from the brain might be explained in terms of an
increase of [
125I]hAb(1-40) efflux transport activity
across the BBB, or a decrease of [
125I]hAb(1-40) binding
to brain parenchymal cells, or both. However, the
k i n e t i cd a t as h o w ni nF i g u r e1i n d i c a t et h a t1 , 2 5 ( O H )
2D3 treatment increased the efflux transport activity, but
did not affect the binding.
The present study examined the [
125I]hAb(1-40) elimi-
nation from the brain for 60 min, and considerable
degradation of injected [
125I]hAb(1-40) might occur dur-
ing this period. However, we showed previously that the
elimination of [
125I]hAb(1-40) from mouse brain was
inhibited to 21.2% by unlabeled hAb(1-40) and that intact
[
125I]hAb(1-40) was detected in plasma after its microin-
jection into rat brain [6,33]. Furthermore, the elimination
of [
125I]hAb(1-40) from rat brain was not significantly
inhibited by L-tyrosine [6]. These results suggest that the
present BEI findings mainly reflect the elimination of
intact [
125I]hAb( 1 - 4 0 )a n dp o s s i b l ya l s ot os o m ee x t e n t
partially-degraded [
125I]hAb(1-40), but not [
125I]L-tyro-
sine, from the brain. It is also possible that free [
125I] was
generated by the degradation of [
125I]hAb(1-40) in the
brain. It was reported that rat brain capillary endothelial
cells possess iodide efflux activity and that the activity
was affected by intracellular ATP level [34]. Therefore,
we cannot rule out the possibility that the enhancement
effect of 1,25(OH)2D3 shown in Figure 1 is partially due
to facilitation of free [
125I] elimination from the brain.
Nevertheless, the reduction of endogenous Ab(1-40) level
in the brain by 1,25(OH)2D3 treatment, as shown in Fig-
ure 3, suggests that, at least, hAb(1-40) elimination from
the brain was enhanced by the treatment.
The biological effects of 1,25(OH)2D3 are mediated by
a mixture of genomic and non-genomic actions. The
genomic action of 1,25(OH)2D3 is mediated by binding
of VDR-retinoid × receptor (RXR) complex at the vita-
min D response elements on target genes. RT-PCR ana-
lysis confirmed the expression of VDR mRNA in mouse
brain capillaries (Figure 4). We previously demonstrated
the expression of RXRs in rat brain capillaries [35].
These results indicate that brain capillary endothelial
cells possess VDR-mediated genomic pathway(s), which
may be involved in the enhancement of Ab efflux trans-
port activity.
As regards non-genomic actions, 1,25(OH)2D3 has
been proposed to play roles in the generation of intra-
cellular second messengers and various signal-transduc-
tion cascades [36,37]. 1,25(OH)2D3 increased the
intracellular level of cAMP in several cell lines as effi-
ciently as did forskolin [30,38], and the MEK-mitogen-
activated protein kinase (MAPK)-extracellular signal-
regulated kinase (ERK) signaling pathway is known to
be activated through elevation of intracellular cAMP.
The present BEI study demonstrated that forskolin
enhanced [
125I]hAb(1-40) elimination from mouse brain
(Figure 4) and the in vitro uptake study showed that for-
skolin increased [
125I]hAb(1-40) internalization into
TM-BBB4 cells, and this action was inhibited by MEK
inhibitor (Figure 6B). These results suggest that the
MEK-MAPK-ERK signaling pathway is involved in
enhancing the brain-to-blood efflux transport of hAb(1-
40) at the BBB. Therefore, 1,25(OH)2D3-mediated
enhancement of brain-to-blood hAb(1-40) efflux trans-
port is likely to involve both genomic and nongenomic
actions of 1,25(OH)2D3. The enhancing effect of forsko-
lin on [
125I]hAb(1-40) elimination (16.4%, Figure 5) is
smaller than that of 1,25(OH)2D3 (25.4%, Figure 1A).
This slight difference may be explained by a difference
in the activating activity of 1,25(OH)2D3 and forskolin
at different doses, although it is also possible that for-
skolin activated only a part of the signaling pathways
activated by 1,25(OH)2D3.
TM-BBB4 cells retain the expression of various mole-
cules and functions of the in vivo BBB [39]. However,
the cells do not have polarity, and internalization into
the cells may therefore reflect both uptake from the
brain to the brain capillary endothelial cells and from
the blood to the brain capillary endothelial cells. The
effect of forskolin in enhancing the [
125I]hAb(1-40)
internalization is likely to reflect enhanced hAb(1-40)
uptake from the brain to the cells, since in vivo forskolin
treatment increased the elimination of [
125I]hAb(1-40)
from the brain (Figure 5). A study of the effect of 1,25
(OH)2D3 on the [
125I]hAb(1-40) internalization by TM-
BBB4 failed to provide consistent results (data not
shown). This may be due to the more complex activa-
tion pathways of 1,25(OH)2D3 than forskolin, as well as
the non-polarized character of TM-BBB4 cells. Optimi-
zation of uptake conditions would be necessary for
further studies. The molecules involved in hAb(1-40)
internalization in TM-BBB4 cells have not yet been
identified. Our previous report using conditionally
immortalized rat brain capillary endothelial cells (TR-
BBB) showed that low-density lipoprotein receptor-
related protein 1 indirectly contributes to [
125I]hAb(1-
40) internalization and a P-glycoprotein substrate, vera-
pamil, did not inhibit the uptake [40].
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AD brain [41-43], and soluble Ab dimers and oligomers
initially generated from Ab monomers are involved in the
impairment of synaptic plasticity and memory [44,45].
Our present findings indicate that 1,25(OH)2D3 modulates
brain-to-blood efflux transport of hAb(1-40) at the BBB,
and we therefore consider that impairment of 1,25(OH)
2D3 signaling leads to a decrease in the brain-to-blood
efflux transport activity of hAb(1-40) at the BBB, which in
turn results in an increase of Ab levels in the brain. Clini-
cal data suggest that low serum 25(OH)D3 is associated
with increased risk of cognitive impairment in elderly peo-
ple [10-12], and higher serum 25(OH)D3 levels were
found to be associated with better cognitive test perfor-
mance in AD patients [14]. Epidemiological studies sup-
port an association between VDR gene polymorphisms in
the ligand-binding site and the development of late-onset
AD [15,16]. These relations between vitamin D status and
AD development seem likely to arise, at least partially,
from impairment of the brain-to-blood Ab efflux transport
activity at the BBB due to attenuation of basal 1,25(OH)
2D3-mediated signaling in brain capillary endothelial cells.
Reduction of Ab in the CNS is considered to be a pri-
mary therapeutic target for AD. Based on our findings
here, 1,25(OH)2D3 appears to be a candidate agent for
reduction of Ab( 1 - 4 0 )l e v e li nt h eb r a i nt h r o u g h
enhancement of Ab elimination across the BBB. The
enhancing effect of 1,25(OH)2D3 was observed at 24 h
after administration, but was not observed at 48 h or 72
h (Figure 2B). This is likely to be due to rapid clearance
of 1,25(OH)2D3 from the circulation, since the plasma
concentration of 1,25(OH)2D3 reaches a maximum
within 2 h and returns to baseline 24 h after i.p. admin-
istration [46]. The first experiment shown in Figure 1
was conducted at 24 h after the treatment, to allow suf-
ficient time for functional expression, which involves
following gene induction, protein synthesis and translo-
cation. Several in vivo studies have examined the effect
of vitamin D3 at 24 h after the last treatment [47-49].
To maintain the enhancing effect, repeated adminis-
tration of 1,25(OH)2D3 would be necessary. However,
an effective dose of 1,25(OH)2D3 might induce adverse
effects such as hypercalcemia, because mice receiving
over 0.1 μgo f1 , 2 5 ( O H ) 2D3 every other day for 2 weeks
had hypercalcemia of over 12 mg/dL [50]. Indeed, mice
exhibited reduced body weight and abnormal behavior
from day 4 during treatment with 1,25(OH)2D3 (1 μg/
day, data not shown).
Several vitamin D analogues appear to induce less
hypercalcemia than 1,25(OH)2D3, but might retain the
Ab-transport-enhancing activity of 1,25(OH)2D3. How-
ever, paricalcitol, a vitamin D analogue, did not signifi-
cantly enhance [
125I]hAb(1-40) elimination from mouse
brain (data not shown). Therefore, 1,25(OH)2D3 and its
analogues are unlikely to be candidate disease-modifying
agents for AD. Nevertheless, since serum 25(OH)D3
levels tend to decrease with aging [51], maintaining a
normal serum level (32 to 70 ng/mL) could be helpful
for prevention of AD. Furthermore, since complex geno-
mic and nongenomic pathways appear to be involved in
the action of 1,25(OH)2D3, separation of these effects by
structural modification might be feasible. The present in
vivo and in vitro results suggest that the increase in
cAMP levels by forskolin might be a candidate pathway
for disease-modification of AD, although the in vivo
effects of forskolin are still poorly understood.
Conclusions
Our results indicate that 1,25(OH)2D3 plays a role in
enhancing the Ab(1-40) efflux transport process at the
BBB. Compounds that activate cAMP signaling may be
candidate therapeutic agents for prevention and treat-
ment of AD through functional modulation of Ab efflux
a tt h eB B B .T M - B B B 4c e l l ss h o u l db eag o o dm o d e lf o r
studying the mechanism of hAb(1-40) efflux transport
at the BBB, and also for screening compounds that
enhance the hAb(1-40) efflux transport activity.
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